Janus Henderson Group
ABOS icon

Janus Henderson Group’s Acumen Pharmaceuticals ABOS Stock Holding History

Janus Henderson Group’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-627,263
Closed -$4.24M – 2639
2021
Q4 		$4.24M Sell
627,263
-232,918
-27% -$2.56M ﹤0.01% 1105
2021
Q3 		$12.8M Buy
+860,181
New +$14.3M 0.01% 868

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
GPC
Guardian Point Capital Charlottesville, Virginia $325M AUM 40.6% 1-Year Est. Return

Janus Henderson Group's ABOS Position: Q1 2022 in Review

Janus Henderson Group sold out of Acumen Pharmaceuticals (ABOS) in Q1 2022, closing a stake of 627,263 shares — an estimated $4.24M sold.

Janus Henderson Group first reported a position in ABOS in Q3 2021 and held it in 2 quarters. The position peaked at $12.8M in Q3 2021. 57 funds tracked by Wall St. Rank hold ABOS as of Q1 2022.

  • Janus Henderson Group reported no remaining Acumen Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Janus Henderson Group sold 627,263 Acumen Pharmaceuticals shares in Q1 2022, an estimated $4.24M.
  • Janus Henderson Group first reported a position in Acumen Pharmaceuticals in Q3 2021 and held it in 2 quarters.
  • Janus Henderson Group's Acumen Pharmaceuticals position peaked at $12.8M in Q3 2021.
  • 57 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q1 2022.

Based on Janus Henderson Group's 13F filing for Q1 2022, filed 16 May 2022.